Brain-penetrant mTOR inhibition clears neurodegenerative aggregates in models but has zero human cognitive-aging endpoint - and mTORC2 is needed for memory

Mechanism-to-outcome gap · confidence 70% · Atlas ID H8

The gap

In animal and cell models, blocking mTOR clears out the toxic protein clumps involved in diseases like Alzheimer's and improves memory-related behaviour - a fairly strong case at the lab level. In fact, one long mouse study found rapamycin actually improved learning and memory and reduced anxiety. There is now one human randomised trial (in tuberous sclerosis, 24 weeks), but it was too short and too disease-specific to answer the ageing question, and both the drug and placebo groups improved about equally. The worry that these drugs also block mTORC2 - which brain cells need for long-term memory - is real, but the study proving that point has not yet been added to this Atlas, so treat it as a reasoned concern rather than a demonstrated fact here.

Technical framing: The preclinical CNS case for mTOR inhibition is unusually deep; the human evidence is thin rather than absent. Aggregate-clearance evidence: SPI2010 rapamycin lowered amyloid-beta and abolished cognitive deficits in an AD mouse model (autophagy-dependent); ZHO2009 mTORC1 inhibition suppressed anatomical/behavioral abnormalities; CAC2010 mapped the mTOR-amyloid-tau triangle onto cognition; TAN2024 (preprint) restored tau-induced metabolic, mitochondrial and cognitive deficits; EHN2008 reversed learning deficits in Tsc2+/- mice. HUMAN EVIDENCE (added 2026-08-30): SAX2026, the TRON multicentre randomised controlled trial, tested everolimus against placebo on memory and executive function in tuberous sclerosis complex (38 randomised, ages 16-60, 24 weeks). Effect sizes were small (Cohen's d 0-0.465) and responder rates were high in BOTH arms (20/23, 87% everolimus vs 9/12, 75% placebo), which the authors attribute to practice and placebo effects - an uninformative trial rather than a positive one. It is disease-specific, short and not an ageing trial, so it does NOT close the cognitive-AGEING gap; but it does mean the previous wording 'every outcome is in animals/models' is no longer true of this corpus. BENEFIT-SIDE CORRECTION (2026-08-30): HAL2012 was previously cited here as a 'cognitive downside signal'. It reports the opposite - chronic rapamycin ENHANCED learning and memory in young mice, BLOCKED age-associated cognitive decline in older mice, and DECREASED anxiety- and depressive-like behaviour, with elevated midbrain monoamines. It belongs on the benefit side of this gap. SOURCING GAP: the mTORC2 liability leg - that mTORC2 supports dendritic protein synthesis, synaptic plasticity and long-term memory consolidation, the arm chronic rapamycin also disrupts - currently has NO supporting study in this corpus. LAM2012 and LEE2024 do not establish it. The conditional Rictor-deletion memory literature that does has not been added, so until it is, treat this leg as an editorial extrapolation rather than an established finding. Net: strong mechanism on both sides of the trade-off (A and M — animal and molecular), no human cognitive-AGEING or neurodegeneration outcome, one uninformative disease-specific human trial, and an unquantified balance between clearing aggregates (mTORC1/autophagy) and preserving plasticity (mTORC2).

The hypothesis

Educated guess: dosing the drug on-and-off, or using a version that only blocks mTORC1 (not mTORC2), might clear out the harmful protein buildup without also damaging the memory-related signalling that needs mTORC2 — but this hasn't been tested in humans at all.

Technical framing: An intermittent or mTORC1-selective, CNS-penetrant regimen enhances autophagic clearance of amyloid/tau/alpha-synuclein enough to slow cognitive decline in early neurodegeneration WITHOUT the mTORC2-dependent memory/plasticity penalty seen with chronic pan-mTOR inhibition. The healthspan-relevant readout (delayed cognitive decline) is therefore achievable but has never been tested in humans.

How it could be tested

Two-step: (i) mouse tauopathy/amyloid models comparing chronic pan-rapamycin vs intermittent vs mTORC1-selective (bi-steric) dosing - endpoints aggregate load, autophagic flux (LC3-II/p62), hippocampal LTP, and Morris-water-maze memory, to isolate the mTORC2/plasticity cost. (ii) A biomarker-anchored early-AD human pilot (CSF/plasma p-tau and amyloid PET as surrogate) on the winning schedule. Prediction: intermittent/selective arms clear aggregates with preserved LTP and memory; chronic pan-inhibition clears aggregates but degrades plasticity.

Related studies

Year	Evidence	Study
2010	A	Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease SPI2010 Connected the longevity drug to a specific age-related disease. Long-term rapamycin prevented memory deficits and lowered toxic amyloid-beta in an Alzheimer's mouse model - and the benefit tracked with INCREASED autophagy in neurons. Suggested that the same autophagy boost that may slow aging could also help clear disease-causing proteins.
2009	A	Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice ZHO2009 mTORC1 inhibition reverses neurological abnormalities in neural Pten-knockout mice.
2010	A	Molecular interplay between mTOR, amyloid-beta, and Tau: effects on cognitive impairments CAC2010 Revealed a vicious cycle: amyloid-beta RAISES mTOR activity, and high mTOR in turn blocks the autophagy needed to clear amyloid and tau - so the disease feeds itself. Rapamycin broke the loop in 3xTg-AD mice, rescuing memory and lowering BOTH amyloid and tau, with autophagy shown to be required for the effect.
2008	A	Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis EHN2008 Rapamycin reverses learning and memory deficits in a Tsc2+/- tuberous sclerosis model.
2024	PP	Targeting mTOR restores tau-induced metabolic, mitochondrial, and cognitive deficits in a tauopathy mouse model TAN2024 In mice engineered to overexpress a phosphomimetic tau variant, one week of rapamycin reversed tau-driven mitochondrial dysfunction and rescued cognitive performance in the Morris water maze - extends the mTOR-autophagy-neurodegeneration link (already seen with Huntington's) to a direct tau-phosphorylation mechanism relevant to Alzheimer's.
2012	A	Chronic inhibition of mTOR by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice HAL2012 Asked whether the lifespan-extending dose of rapamycin harms or helps the aging BRAIN. Reassuringly, it enhanced learning and memory in young mice, prevented age-related cognitive decline in old ones, and even reduced anxiety and depression-like behavior - linked to boosted brain monoamines. Cognitive benefit, not cost.
2026	H	Everolimus for the treatment of neuropsychological deficits in tuberous sclerosis complex: findings from the TRON multicentre randomised controlled trial SAX2026 In a multicentre RCT of TSC patients (n=38 randomised, 2:1 everolimus:placebo), 24 weeks of everolimus produced similarly large 'responder' rates for neuropsychological improvement as placebo (87% vs 75%), suggesting large practice/placebo effects rather than a clear drug benefit on cognition -- despite everolimus's established efficacy for TSC tumours and epilepsy. Adverse events were more frequent with everolimus (88% vs 61.5%).
2012	A	Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity LAM2012 In mice, chronic rapamycin also disrupts mTORC2, causing insulin resistance; lifespan extension can be uncoupled from this side effect.
2024	S	Targeting ageing with rapamycin and its derivatives in humans: a systematic review LEE2024 The first systematic review of rapamycin/rapalogs in humans for aging. Screened 18,400 articles, included 19 studies. Found improvements in immune, cardiovascular, and skin (integumentary) parameters; NO significant effect on endocrine, muscular, or neurological systems. No serious adverse events in healthy people, but more infections and raised cholesterol/triglycerides in people with age-related disease. This is the highest-tier human-evidence summary in the whole Atlas - it aggregates many individual human studies rather than reporting one.

← All open questions